Effective treatment of glioblastoma (GBM) remains a formidable challenge. Survival rates
remain poor despite decades of clinical trials of conventional and novel, biologically …

The blood-brain barrier (BBB) presents a formidable obstacle to the effective delivery of
systemically administered pharmacological agents to the brain, with~ 5% of candidate drugs …

Canine brain tumours are becoming established as naturally occurring models of disease to
advance diagnostic and therapeutic understanding successfully. The size and structure of …

Background The interleukin-13 receptor alpha 2 (IL13RA2) and ephrin type A receptor 2
(EPHA2) are attractive therapeutic targets, being expressed in~ 90% of canine and human …

Diffuse intrinsic pontine gliomas (DIPGs) are a pontine subtype of diffuse midline gliomas
(DMGs), primary central nervous system (CNS) tumors of childhood that carry a terrible …

Convection enhanced delivery (CED) allows direct intracranial administration of neuro-
therapeutics. Success of CED relies on specific targeting and broad volume distributions …

Transformative advances in MRI over the past 3 decades allow for the detailed
neuroanatomic characterization and presumptive antemortem diagnosis of many canine and …

The blood-brain barrier, essential for protecting the central nervous system, also restricts
drug delivery to this region. Thus, delivering drugs across the blood-brain barrier is an active …

Convection-enhanced delivery is a technique to bypass the blood–brain barrier and deliver
therapeutic drugs into the brain tissue. However, animal investigations and preliminary …

ABSTRACT A significant obstacle to the development of new brain tumor therapeutics
remains the lack of rodent models that faithfully reproduce the in vivo complexities of human …